Navigation Links
Drive for good quality medicines, foods reinforced by USP agreements with Chinese drug authorities
Date:6/19/2009

Rockville, Md., June 19, 2009 As part of its efforts to improve the quality of medicines and food ingredients worldwide, the U.S. Pharmacopeial (USP) Convention this week reached three new cooperative agreements with Chinese drug control authorities. Because Chinese manufacturers supply so much of the world's drug and food ingredients, these agreementscoupled with three previous agreements between USP and other government organizations in Chinamark a significant commitment to ensure that concerns about quality are addressed. USP is a scientific, nonprofit organization that sets standards for the quality of prescription and over-the-counter drugs that are enforced by the U.S. Food and Drug Administration (FDA) in the United States. USP also sets standards for the quality of food ingredients and dietary supplements; these and USP's drug standards are used in more than 130 countries.

At a June 18 ceremony in Guangzhou, China, where he signed a Memorandum of Understanding (MOU) with the Guangzhou Municipal Institute of Drug Control, Roger L. Williams, M.D., USP's chief executive officer, said, "I am impressed at the energy and commitment of the Chinese people as they work to bring good quality medicines to consumers and patients in China and around the world. We are united in that goal." Mr. Yingqiao Jiang, head of the Guangzhou Institute, observed, "Chinese manufacturers share that commitment with regulatory bodies such as the Guangzhou Institute and organizations like USP. We are pleased to work together to help ensure the quality of medicines and their ingredients."

Earlier this week, USP also signed MOUs with the Beijing Municipal Institute of Drug Control and the Zhejiang Institute for Food and Drug Control. All are focused on strengthening the relationships through such initiatives as scientist exchange programs, joint standards- and testing-related work, and other projects to improve drug quality that will benefit from the expertise of both parties.

As a result of a 2008 agreement, USP and the Chinese Pharmacopoeia Commission (ChP) agreed this week to jointly develop standards for active pharmaceutical ingredients that have been singled out by the U.S. FDA and China State Food and Drug Administration (SFDA) as being especially important to help ensure quality medicines for patients and practitioners.

Based in the United States, USP has offices and laboratories in Shanghai, China; Hyderabad, India; and So Paulo, Brazil; USP also has offices in Basel, Switzerland. USP has formed similar partnerships in support of good quality medicines and food ingredients in these and other countries throughout the world.


'/>"/>

Contact: Francine Pierson
fp@usp.org
301-816-8588
US Pharmacopeia
Source:Eurekalert

Related medicine news :

1. Teamsters Call on United Way to Aid Frontline Blood Drive Workers
2. New Therapies, Including Novel Biologic Agents from Elan/Wyeth and Eli Lilly, Will Drive Robust 11 Percent Annual Growth In the Alzheimers Disease Market
3. Mom on Mission for Quality, Affordable Healthcare for All Drives Purple Bus Across Nation Gathering Stories
4. Pay Attention to Signs That Say Youre Too Tired to Drive
5. Screening Programs to Drive European GI Videoscope Market Despite Economic Downturn, According to Millennium Research Group
6. Availability of diagnostic tests drive success in hospitalist-run short-stay units
7. Advances in Medical Technology Identified as a Primary Driver of Increased Costs
8. Health Plans Prepare for Health Care Reform: Comparative Effectiveness, Consumerism Drive Future Changes, According to Deloitte Study
9. Sparta Systems Launches Hong Kong Operations to Drive Enterprise Quality and Compliance in Asia-Pacific Region
10. Record 73.4 Million Pounds Collected in Letter Carriers National Food Drive
11. Amgens Denosumab and Eli Lillys Forteo/Forsteo Will Drive Robust Annual Growth in the Osteoporosis Drug Market From 2013 to 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... While EHR data has revolutionized ... an innovative workstation designed to reduce nursing fatigue while enhancing productivity. Based on ... offers a lightweight, highly mobile, multi-functional alternative to the limitations of handheld computing. ...
(Date:2/17/2017)... FL (PRWEB) , ... February 17, 2017 , ... ... software tools that allow for the electronic prescribing of controlled and non-controlled substances ... , Ninety percent of pharmacies in the United States now accept electronic prescriptions, ...
(Date:2/17/2017)... (PRWEB) , ... February 17, ... ... Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. 22, 2017 — ... are the critical reimbursement questions manufacturers should be asking before selecting an ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... a Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. – ... between corrective action (CA) and preventive action (PA)? , The methods share techniques ...
(Date:2/17/2017)... Springs, Texas (PRWEB) , ... February 17, 2017 ... ... Signature 8.0 at the HIMSS17 Conference & Exhibition in Orlando, Fla., February 19-23. ... latest version of the most widely used electronic patient signatures solution in ...
Breaking Medicine News(10 mins):
(Date:2/18/2017)... Research and Markets has announced the addition of the "Contraceptives - ... ... the US, Canada , Japan , ... Latin America , and Rest of World. Annual estimates and forecasts ... analysis is provided for these markets. Market data and analytics are derived ...
(Date:2/17/2017)... 2017  Ethicon, Inc. today announced a definitive ... held medical device company that manufactures and markets ... novel minimally invasive device for the surgical treatment ... enable Ethicon to offer patients a safe and ... surgical procedure. 1 This LINX ...
(Date:2/17/2017)... Theravance Biopharma, Inc. (NASDAQ: ... announced the presentation of positive clinical data for ... kinase (JAK) inhibitor designed to be intestinally restricted, ... European Crohn,s and Colitis Organization (ECCO). In a ... its completed Phase 1 study of single-ascending and ...
Breaking Medicine Technology: